Urogen Pharma Stock Today
| URGN Stock | USD 14.21 0.32 2.20% |
Performance0 of 100
| Odds Of DistressOver 85
|
UroGen Pharma is selling at 14.21 as of the 25th of April 2024; that is -2.2% down since the beginning of the trading day. The stock's open price was 14.53. UroGen Pharma has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for UroGen Pharma are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of March 2024 and ending today, the 25th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 4th of May 2017 | Category Healthcare | Classification Health Care |
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey. Urogen Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 34.12 M outstanding shares of which 4.2 M shares are at this time shorted by private and institutional investors with about 9.45 trading days to cover. More on UroGen Pharma
Moving against UroGen Stock
| 0.76 | CGC | Canopy Growth Corp Trending | PairCorr |
| 0.7 | ACB | Aurora Cannabis Trending | PairCorr |
| 0.53 | XFOR | X4 Pharmaceuticals Buyout Trend | PairCorr |
| 0.43 | ELEV | Elevation Oncology Earnings Call This Week | PairCorr |
| 0.42 | ELYM | Eliem Therapeutics | PairCorr |
| 0.42 | NRSNW | NeuroSense Therapeutics | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 9th of May 2024
UroGen Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. UroGen Pharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding UroGen Pharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO, Director | Ron Bentsur | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Biotechnology, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering UroGen Pharma report their recommendations after researching UroGen Pharma's financial statements, talking to executives and customers, or listening in on UroGen Pharma's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering UroGen Pharma. The UroGen consensus assessment is calculated by taking the average forecast from all of the analysts covering UroGen Pharma. | ||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key measurements obtained from UroGen Pharma's financial statements, UroGen Pharma may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. Financial strength of UroGen Pharma is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||
UroGen Pharma's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to UroGen Pharma's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand UroGen Pharma's financial leverage. It provides some insight into what part of UroGen Pharma's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
UroGen Pharma (URGN) is traded on NASDAQ Exchange in USA. It is located in 400 Alexander Park Drive, Princeton, NJ, United States, 08540 and employs 198 people. UroGen Pharma is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 472.93 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate UroGen Pharma's market, we take the total number of its shares issued and multiply it by UroGen Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. UroGen Pharma conducts business under Biotechnology sector and is part of Health Care industry. The entity has 34.12 M outstanding shares of which 4.2 M shares are at this time shorted by private and institutional investors with about 9.45 trading days to cover.
UroGen Pharma currently holds about 111.74 M in cash with (76.38 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.91.
Check UroGen Pharma Probability Of Bankruptcy
Ownership AllocationUroGen Pharma maintains a total of 34.12 Million outstanding shares. The majority of UroGen Pharma outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in UroGen Pharma to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in UroGen Pharma. Please pay attention to any change in the institutional holdings of UroGen Pharma as this could imply that something significant has changed or is about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check UroGen Ownership Details
UroGen Stock Price Odds Analysis
Contingent on a normal probability distribution, the odds of UroGen Pharma jumping above the current price in 90 days from now is about 84.0%. The UroGen Pharma probability density function shows the probability of UroGen Pharma stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days UroGen Pharma has a beta of 0.5692. This usually implies as returns on the market go up, UroGen Pharma average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding UroGen Pharma will be expected to be much smaller as well. Additionally, uroGen Pharma has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of UroGen Pharma to move above the current price in 90 days from now is about 84.0 (This UroGen Pharma probability density function shows the probability of UroGen Stock to fall within a particular range of prices over 90 days) .
UroGen Pharma Historical Income Statement
UroGen Pharma Income Statement is one of the three primary financial statements used for reporting UroGen's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of UroGen Pharma revenue and expense. UroGen Pharma Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, UroGen Pharma's Depreciation And Amortization is very stable compared to the past year. As of the 25th of April 2024, Tax Provision is likely to grow to about 1.2 M, while Operating Income is likely to drop (68.8 M). View More FundamentalsUroGen Stock Against Markets
Picking the right benchmark for UroGen Pharma stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in UroGen Pharma stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for UroGen Pharma is critical whether you are bullish or bearish towards UroGen Pharma at a given time. Please also check how UroGen Pharma's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in UroGen Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Fundamentals Comparison Now
Fundamentals ComparisonCompare fundamentals across multiple equities to find investing opportunities |
| All Next | Launch Module |
UroGen Pharma Corporate Directors
UroGen Pharma corporate directors refer to members of an UroGen Pharma board of directors. The board of directors generally takes responsibility for the UroGen Pharma's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of UroGen Pharma's board members must vote for the resolution. The UroGen Pharma board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Ran Nussbaum | Director | Profile | |
| Stuart Holden | Independent Director | Profile | |
| Chaim Hurvitz | Director | Profile | |
| Pini Orbach | Independent Director | Profile |
How to buy UroGen Stock?
Before investing in UroGen Pharma, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in UroGen Pharma. To buy UroGen Pharma stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of UroGen Pharma. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase UroGen Pharma stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located UroGen Pharma stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased UroGen Pharma stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as UroGen Pharma, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy UroGen Stock please use our How to Invest in UroGen Pharma guide.
Already Invested in UroGen Pharma?
The danger of trading UroGen Pharma is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of UroGen Pharma is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than UroGen Pharma. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile UroGen Pharma is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether UroGen Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of UroGen Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Urogen Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Urogen Pharma Stock: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UroGen Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.Note that the UroGen Pharma information on this page should be used as a complementary analysis to other UroGen Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Complementary Tools for UroGen Stock analysis
When running UroGen Pharma's price analysis, check to measure UroGen Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy UroGen Pharma is operating at the current time. Most of UroGen Pharma's value examination focuses on studying past and present price action to predict the probability of UroGen Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move UroGen Pharma's price. Additionally, you may evaluate how the addition of UroGen Pharma to your portfolios can decrease your overall portfolio volatility.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is UroGen Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.55) | Revenue Per Share 2.869 | Quarterly Revenue Growth 0.301 | Return On Assets (0.26) | Return On Equity (14.81) |
The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.